Literature DB >> 16020580

N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration.

S J Shalansky, G E Pate, A Levin, J G Webb.   

Abstract

Dose and route of administration of N-acetylcysteine are key factors to consider when evaluating whether this agent is effective in preventing radiocontrast induced nephropathy.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16020580      PMCID： PMC1769030          DOI： 10.1136/hrt.2004.053579

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


  15 in total

1.  Water for contrast-induced nephropathy? A thirst for knowledge.

Authors:  Gordon E Pate; John G Webb
Journal:  J Invasive Cardiol       Date:  2003-12       Impact factor: 2.022

Review 2.  N-acetylcysteine in the prevention of radiocontrast-induced nephropathy.

Authors:  Steven Fishbane; John H Durham; Kevin Marzo; Michael Rudnick
Journal:  J Am Soc Nephrol       Date:  2004-02       Impact factor: 10.121

3.  Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.

Authors:  M Tepel; M van der Giet; C Schwarzfeld; U Laufer; D Liermann; W Zidek
Journal:  N Engl J Med       Date:  2000-07-20       Impact factor: 91.245

4.  Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity.

Authors:  Carlo Briguori; Antonio Colombo; Anna Violante; Pasquale Balestrieri; Fiore Manganelli; Pietro Paolo Elia; Bruno Golia; Stefano Lepore; Guido Riviezzo; Pierfranco Scarpato; Amelia Focaccio; Mariateresa Librera; Erminio Bonizzoni; Bruno Ricciardelli
Journal:  Eur Heart J       Date:  2004-02       Impact factor: 29.983

5.  Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy.

Authors:  Daniel W Isenbarger; Steven M Kent; Patrick G O'Malley
Journal:  Am J Cardiol       Date:  2003-12-15       Impact factor: 2.778

6.  Acetylcysteine for prevention of contrast nephropathy: meta-analysis.

Authors:  Rainer Birck; Stefan Krzossok; Florian Markowetz; Peter Schnülle; Fokko J van der Woude; Claude Braun
Journal:  Lancet       Date:  2003-08-23       Impact factor: 79.321

7.  Pharmacokinetics of N-acetylcysteine in man.

Authors:  L Borgström; B Kågedal; O Paulsen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials.

Authors:  Alvaro Alonso; Joseph Lau; Bertrand L Jaber; Andrew Weintraub; Mark J Sarnak
Journal:  Am J Kidney Dis       Date:  2004-01       Impact factor: 8.860

9.  The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable.

Authors:  Ute Hoffmann; Michael Fischereder; Bernd Krüger; Wolfgang Drobnik; Bernhard K Krämer
Journal:  J Am Soc Nephrol       Date:  2004-02       Impact factor: 10.121

10.  A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study.

Authors:  Christopher S R Baker; Andrew Wragg; Sanjay Kumar; Rodney De Palma; Laurence R I Baker; Charles J Knight
Journal:  J Am Coll Cardiol       Date:  2003-06-18       Impact factor: 24.094
View more
  7 in total

1.  Preventing radiocontrast-induced nephropathy in chronic kidney disease patients undergoing coronary angiography.

Authors:  Yao-Min Hung; Shoa-Lin Lin; Shih-Yuan Hung; Wei-Chun Huang; Paul Yung-Pou Wang
Journal:  World J Cardiol       Date:  2012-05-26

2.  Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models.

Authors:  D Thomas Dickey; Leslie L Muldoon; Nancy D Doolittle; Darryl R Peterson; Dale F Kraemer; Edward A Neuwelt
Journal:  Cancer Chemother Pharmacol       Date:  2007-10-02       Impact factor: 3.333

3.  Protective properties of 2-acetylcyclopentanone in a mouse model of acetaminophen hepatotoxicity.

Authors:  Lihai Zhang; Terrence Gavin; Brian C Geohagen; Qiang Liu; Katherine J Downey; Richard M LoPachin
Journal:  J Pharmacol Exp Ther       Date:  2013-06-12       Impact factor: 4.030

4.  Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials.

Authors:  Zikai Sun; Qiang Fu; Longxing Cao; Wen Jin; Lingling Cheng; Zhiliang Li
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

5.  N-acetylcysteine does not prevent contrast nephropathy in patients with renal impairment undergoing emergency CT: a randomized study.

Authors:  Pierre-Alexandre Poletti; Alexandra Platon; Sophie De Seigneux; Elise Dupuis-Lozeron; François Sarasin; Christoph D Becker; Thomas Perneger; Patrick Saudan; Pierre-Yves Martin
Journal:  BMC Nephrol       Date:  2013-06-03       Impact factor: 2.388

Review 6.  Mitochondria: a new therapeutic target in chronic kidney disease.

Authors:  Simona Granata; Alessandra Dalla Gassa; Paola Tomei; Antonio Lupo; Gianluigi Zaza
Journal:  Nutr Metab (Lond)       Date:  2015-11-25       Impact factor: 4.169

7.  Prophylactic efficacy of some chemoprotectants against abrin induced lethality.

Authors:  Nandita Saxena; Yangchen Doma Bhutia; Om Kumar; Pooja Phatak; Ramesh Kumar Kaul
Journal:  Interdiscip Toxicol       Date:  2019-03-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.